Inhibikase Therapeutics, Inc. $IKT

What the company doesAI summary of filing

Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing IKT-001, an oral prodrug of imatinib, for the treatment of pulmonary arterial hypertension (PAH), a rare and progressive lung disease. The company does not generate revenue and is focused on advancing IKT-001 through a Phase 3 clinical trial called IMPROVE-PAH, which it initiated in 2025 following FDA guidance to transition from a planned Phase 2b study. Inhibikase also holds intellectual property rights to IKT-001 with patent protection in the United States until 2039 and potential extensions until 2044, and it previously developed product candidates for infectious diseases and neurodegeneration before refocusing its resources on the PAH indication. The company relies on third-party contract manufacturers and has no approved products or sales capabilities to date. [10-K 2026-03-26]

Segments: IKT-001 for pulmonary arterial hypertension